Genitourinary Cancers

Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the National Comprehensive Cancer Network Annual Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors. Read More ›

An analysis from the ARASENS trial showed that the addition of darolutamide to androgen-deprivation therapy and docetaxel significantly improved overall survival in subgroups of patients with metastatic hormone-sensitive prostate cancer with high-volume and high-risk disease, contributing to the evidence that this combination should be considered the new standard of care for this patient population. Read More ›

The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD, Associate Professor, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium. Read More ›

Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease. Read More ›

Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial

At the 2018 Genitourinary Cancers Symposium, lead investigator Alison Jane Birtle, MD, MBBS, MRCP, FRCR, presented the results of the phase 3 POUT clinical trial, which showed that adjuvant chemotherapy had impressive gains in the disease-free survival and metastasis-free survival in upper-tract urothelial cancer

Read More ›

Androgen deprivation therapy (ADT) for the treatment of prostate cancer has adverse effects that may be difficult for men to tolerate. Read More ›

Monitoring for Bone Health
Dianna Shafer talks about the testing protocol when examining patients’ bones and what they prescribe to ensure their patients’ bone health is being addressed. Read More ›

Treatment When Cancer Metastasizes

Skeletal-Related Events for Bone Metastases
Pam Skurkay, Dianna Shafer, and Angela Hunter discuss the rates of incidences of this issue as well as the benefits of using Xgeva, including a better quality of life for patients. Read More ›

Patients with Metastatic Prostate Cancer

Page 1 of 6


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: